MAY 14, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S. Knight, founding partner of Generation Investment Management, to its Board of Directors. Knight and his partners, former Vice President Al Gore and David Blood, founded Generation Investment Management, a leading […]
FEBRUARY 28, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it had been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN brings together dozens of institutions to help accelerate the translation of biomarker information into clinical applications and to […]
NOVEMBER 29, 2017 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced the appointments of Stephen Squinto, Ph.D., and Gary Rubin, CPA, to its Board of Directors. Dr. Squinto is a Venture Partner with OrbiMed Healthcare Fund Management. He previously co-founded Alexion Pharmaceuticals, Inc., a global biopharmaceutical company focused […]
MAY 3, 2017 (SAN ANTONIO, TX ) bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030. The EPO patent, titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine […]
NOVEMBER 15, 2016 (SAN ANTONIO, TX) bioAffinity Technologies announced that the government of the Hong Kong Special Administrative Region has awarded a Certificate of Grant of Standard Patent for the Company’s proprietary CyPath© technology for the early detection of lung cancer. The Hong Kong patent, titled “System and Method for Analyzing Samples Labeled with 5, […]
AUGUST 24, 2016 (SAN ANONIO, TX) bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the CyPath® assay for the early detection of cancer and the prognosis of the patient response to cancer therapy. The U.S. Patent, entitled “5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) and Kit […]